Mirum Pharmaceuticals, Inc.
Raised
$68M
Investors
2
Min Invest
$0
AltStreet Analysis
·Generated from EDGAR primary sources
Mirum Pharmaceuticals, Inc., a Delaware corporation, filed this Form D on January 29, 2026, reporting $68.5M in equity raised under Rule 506(c) from 2 investors with no stated minimum investment. The filing lists 11 related persons including executives Christopher Peetz, Eric Bjerkholt, and Peter Radovich. First sale date was not disclosed.
This filing is categorized under real_estate but appears to be a pharmaceutical company based on entity name and executive structure, suggesting a data classification error. The 506(c) exemption with no minimum investment and $34.25M average check size indicates institutional or accredited investor participation rather than typical real estate crowdfunding patterns.
Data Flags
EDGAR Filing Data
Form D — Primary Source
View on SEC.govRelated Persons (Form D)
Executive officers, directors, and promoters listed on the SEC Form D filing. Source: SEC.gov.
Christopher Peetz
Executive Officer, Director · Foster City, CA
Eric Bjerkholt
Executive Officer · Foster City, CA
Peter Radovich
Executive Officer · Foster City, CA
Laura Brege
Director · Foster City, CA
Timothy Walbert
Director · Foster City, CA
William Fairey
Director · Foster City, CA
Patrick Heron
Director · Foster City, CA
Lon Cardon
Director · Foster City, CA
Saira Ramasastry
Director · Foster City, CA
Laurent Fischer
Director · Foster City, CA
Michael Grey
Director · Foster City, CA
Is this your offering?
Claim this profile to add contact information, team members, LinkedIn profiles, fund history, and additional financial data. EDGAR-sourced data and AltStreet analysis cannot be edited, but corrections can be requested for verifiable inaccuracies.
Data Methodology
Capital raise figures, investor counts, and filing dates are sourced directly from SEC EDGAR Form D primary documents via the SEC EDGAR submissions API and full-text search index. AltStreet analysis (summaries, flags, category context) is generated by Claude from this primary source data and reviewed for accuracy. Platform-provided information (if present) is clearly labeled and does not affect EDGAR data or AltStreet editorial coverage. EDGAR data is verified read-only — platforms may request factual corrections for demonstrable inaccuracies by contacting research@altstreet.investments. This page does not constitute investment advice.
